Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Boehringer Ingelheim
Dow
Express Scripts
McKesson

Last Updated: November 29, 2022

CLINICAL TRIALS PROFILE FOR GADOTERATE MEGLUMINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Gadoterate Meglumine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00650845 ↗ Renal Safety Evaluation After DotaremĀ®-Enhanced MRI Completed Guerbet Phase 4 2008-01-01 Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial. The aim of this study was to evaluate the safety profile of gadoterate meglumine (DotaremĀ®) in patients with chronic renal insufficiency by evaluating the rate of patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate meglumine.
NCT01010932 ↗ Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) Completed Guerbet Phase 3 2009-10-01 The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
NCT01012674 ↗ Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) Completed Guerbet Phase 3 2009-10-01 The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
NCT01254552 ↗ Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis Completed Guerbet Phase 4 2010-08-01 The study aimed to prospectively investigate the prevalence of myocardial scar on Dotarem-enhanced Cardiovascular Magnetic Resonance Imaging (MRI) in asymptomatic patients with type-2 Diabetes Mellitus and to assess its correlation with subclinical coronary artery disease on Cardiac Computed Tomography Angiography (CCTA).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gadoterate Meglumine

Condition Name

Condition Name for Gadoterate Meglumine
Intervention Trials
Breast Diseases 2
Cerebral Arterial Diseases 2
Breast Cancer 1
Hepatocellular Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gadoterate Meglumine
Intervention Trials
Breast Neoplasms 2
Cerebral Arterial Diseases 2
Renal Insufficiency 2
Breast Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gadoterate Meglumine

Trials by Country

Trials by Country for Gadoterate Meglumine
Location Trials
United States 8
Korea, Republic of 3
France 2
Belgium 2
Italy 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gadoterate Meglumine
Location Trials
Illinois 2
Massachusetts 2
Indiana 2
North Carolina 1
Arizona 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gadoterate Meglumine

Clinical Trial Phase

Clinical Trial Phase for Gadoterate Meglumine
Clinical Trial Phase Trials
Phase 4 6
Phase 3 2
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gadoterate Meglumine
Clinical Trial Phase Trials
Completed 7
Recruiting 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gadoterate Meglumine

Sponsor Name

Sponsor Name for Gadoterate Meglumine
Sponsor Trials
Guerbet 10
University of Chicago 1
Bayer AG (Sponsor) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gadoterate Meglumine
Sponsor Trials
Industry 11
Other 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Merck
Moodys
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.